Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ: BNTX )

119.83 -2.95 (-2.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
65 66 Next >
BioNTech Earnings Preview
Via Benzinga
4 Analysts Have This to Say About BioNTech
Via Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization. 
Via Benzinga
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks
The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk. 
Via Benzinga
Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders
Moderna CEO Stephane Bancel will face a Senate Committee over pricing plans. 
Via Investor's Business Daily
Price Over Earnings Overview: BioNTech
Via Benzinga
BioNTech Q4 2022 Earnings Conference Call On March 27, 2023 At 08:00 AM ET
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose
From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector. 
Via Benzinga
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
From BioNTech SE
Via GlobeNewswire
7 Stocks Set to Soar When the Market Recovers
Daring contrarians can bid up the danger with these intriguing market ideas. 
Via InvestorPlace
FDA Approves Pfizer/BioNTech's Bivalent COVID-19 Vaccine For Youngest Kids
Via Benzinga
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr. 
Via Benzinga
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
From BioNTech SE
Via GlobeNewswire
Wall Street Thinks These 2 Undervalued Stocks Have Exceptional Growth Potential
They're both facing the same fierce headwind, and it won't be going away soon. 
Via The Motley Fool
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising
Via Benzinga
European Commission Keeps Mum On Talks Regarding Pfizer COVID-19 Vaccine Contract: Report
European Commission President Ursula von der Leyen remains silent on her dealings with Pfizer Inc (NYSE: PFE) regarding the EU's COVID-19 vaccine contract is hurting public trust. 
Via Benzinga
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
From BioNTech SE
Via GlobeNewswire
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Pfizer/BioNTech Seek Expanded Approval For Its Updated COVID-19 Shot As Primary Series Vaccination
Via Benzinga
Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop
The company is doubling down on its vaccine success. 
Via The Motley Fool
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Shares crumbled after Moderna's flu shot outperformed in just one flu strain. 
Via Investor's Business Daily
Why Is Moderna (MRNA) Stock Down 5% Today?
If Moderna's new formulation works the latest failure will be a short-term hiccup. But MRNA stock also faces legal and PR challenges. 
Via InvestorPlace
Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents
Via Benzinga
Is Novavax Stock a Buy With the New Normal for COVID?
The landscape has shifted dramatically in the COVID-19 vaccine market. 
Via The Motley Fool
The 3 Most Undervalued Growth Stocks for Your February Buy List
These undervalued growth stocks have the value and projected growth that investors seek when researching their next investment decisions. 
Via InvestorPlace
Better Buy: Novavax or BioNTech Stock?
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot. 
Via The Motley Fool
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.